Amended Statement of Beneficial Ownership (sc 13d/a)
August 14 2017 - 5:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE 13D/A
Under
the Securities Exchange Act of 1934
(Amendment
No. 3)*
Aclaris
Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00461U 105
(CUSIP Number)
ALBERT CHA
VIVO CAPITAL, LLC
505 HAMILTON AVENUE, SUITE 207
PALO ALTO, CA 94301
TELEPHONE: (650) 688-0818
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)
March 15, 2017
(Date of Event Which Requires Filing
of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note
: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are
to be sent.
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the
remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however,
see
the
Notes
).
|
|
|
|
|
|
|
1.
|
|
Name of Reporting Persons
Vivo Ventures VII, LLC
I.R.S. Identification Number of above person: 27-4484686
|
2.
|
|
Check the Appropriate Box if a Member of a Group (see instructions)
(a)
☐
(b)
☐
|
3.
|
|
SEC USE ONLY
|
4.
|
|
Source of Funds (see instructions)
OO
|
5.
|
|
Check if Disclosure of Legal Proceedings Is Required Pursuant
to Item 2(d) or 2(e)
☐
|
6.
|
|
Citizenship or Place of Organization:
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
2,858,569 shares of Common Stock (1)
|
|
8.
|
|
Shared Voting Power
0
|
|
9.
|
|
Sole Dispositive Power
2,858,569 shares of Common Stock (1)
|
|
10.
|
|
Shared Dispositive Power
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting
Person:
2,858,569 shares of Common Stock (1)
|
12.
|
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(see instructions)
☐
|
13.
|
|
Percent of Class Represented by Amount in Row 11:
9.5% (2)
|
14.
|
|
Type of Reporting Person (see instructions):
OO
|
(1)
|
Consists of 2,797,597 shares of Common Stock held by Vivo Ventures Fund VII, L.P. and 60,972 shares of Common Stock held by Vivo Ventures VII Affiliates Fund, L.P. Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. The voting members of Vivo Ventures VII, LLC are Dr. Frank Kung, Dr. Albert Cha, Dr. Edgar Engleman, Dr. Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.
|
(2)
|
This percentage is calculated based on 29,996,517 shares
of Common Stock, par value $0.0001, of the Issuer outstanding after the completion of the Issuer’s offering, as disclosed
in the final prospectus filed by the Issuer on August 11, 2017, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as
amended, which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-214384). The Reporting Person’s
beneficial ownership increased solely due to an increase in the total number of shares of the Issuer’s Common Stock outstanding.
|
SCHEDULE 13D/A
Explanatory Note
: This Amendment No. 3 (the “Amendment”),
which amends and supplements the statement on Schedule 13D, filed on October 20, 2015, as amended by Amendment No. 1 to Schedule
13D, filed on November 21, 2016 and Amendment No. 2 to Schedule 13D, filed on March 3, 2017 (collectively, the “Prior 13D
”) by the Reporting Person, relates to the common stock, par value $0.00001 per share (the “Common Stock”) of
Aclaris Therapeutics, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of
the Issuer is 101 Lindenwood Drive, Suite 400, Malvern, PA 19355.
The purpose of this Amendment is to report changes in the Reporting
Person’s beneficial ownership of the Issuer’s Common Stock, which resulted solely due to increases in the total number
of shares of the Issuer’s Common Stock outstanding. Except as specifically provided herein, this Amendment does not modify
any of the information previously reported on the Prior 13D. All capitalized terms contained herein but not otherwise defined shall
have the meanings ascribed to such terms in the Prior 13D.
Item 5. Interest in Securities of the Issuer
This Amendment amends and restates Item 5 of the Prior 13D in
its entirety as set forth below:
(a) The number and percentage of Common Stock beneficially owned
by the Reporting Person on the date of each event that requires filing of this Amendment are as follows:
Date of Event: March 15, 2017
Record Holder
|
Number of Shares of Common Stock
|
Percent of Outstanding Common Stock*
|
Vivo Ventures Fund VII, L.P.
|
2,797,597
|
10.7%
|
Vivo Ventures VII Affiliates Fund, L.P.
|
60,972
|
0.2%
|
Total:
|
2,858,569
|
11.0%
|
* The percentages are calculated based on 26,088,866
shares of the Issuer’s Common Stock outstanding as of March 14, 2017, as reported in the Issuer’s annual report
on Form 10-K for the period ended December 31, 2016 and filed on March 15, 2017.
Date of Event: August 11, 2017
Record Holder
|
Number of Shares of Common Stock
|
Percent of Outstanding Common Stock*
|
Vivo Ventures Fund VII, L.P.
|
2,797,597
|
9.3%
|
Vivo Ventures VII Affiliates Fund, L.P.
|
60,972
|
0.2%
|
Total:
|
2,858,569
|
9.5%
|
* The percentages are calculated based on 29,996,517
shares of the Issuer’s Common Stock outstanding after the completion of the Issuer’s offering, as disclosed in the
final prospectus filed by the Issuer on August 11, 2017, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended,
which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-214384).
(b) The Reporting Person has sole voting and dispositive power
for the Common Stock the Reporting Person beneficially owns.
(c) The Reporting Person has not effected any transactions in
the securities of the Issuer during the past 60 days before August 11, 2017 or March 15, 2017, the dates of the events reported
on this Amendment.
(d) Not Applicable.
(e) Not Applicable.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.
Date: August 14, 2017
|
Vivo Ventures VII, LLC
|
|
|
|
|
By:
|
/s/ Albert Cha
|
|
|
Albert Cha
|
|
|
Managing Member
|
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024